Chronic Kidney Disease Trial, Recruiting NCT05970341 Sponsor: University of Texas at Austin Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT05970341
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who receive primary care at one of three Harris Health clinics: Smith Clinic, Harris Health Outpatient Center (on the LBJ campus), or Martin Luther King Jr. Health Center (MLK)
  • People who have had at least one visit at the clinic in the past 18 months (not a first-time patient)
  • People diagnosed with early-to-moderate chronic kidney disease (CKD Stage 2, 3a, or 3b), or early/undiagnosed kidney disease with certain protein levels in the urine (confirm with trial site)
  • People whose most recent blood potassium level, tested within the past 12 months, was at or below a certain level (confirm with trial site)
  • People who speak English or Spanish
  • People who are able to participate in the program for at least 6 months
  • People who are able to clean, prepare, and store (refrigerate or freeze) food products provided through the trial
  • People who have access to receive text messages (SMS) on a mobile phone
  • People whose preferred delivery address falls within an available delivery zone

Who may not be able to join:

  • People with more advanced kidney disease (CKD Stage 4), end-stage kidney disease, or who are currently on dialysis
  • People who regularly take certain pain medications called NSAIDs (such as ibuprofen) more than twice a week for 90 days or longer, as these can affect potassium levels
  • People who take a type of medication called mineralocorticoid receptor antagonists (confirm with trial site for examples)
  • People who take the blood-thinning medication Warfarin
  • People with certain specific kidney conditions — such as polycystic kidney disease, glomerulonephritis, lupus-related kidney disease, or a condition called ANCA-associated vasculitis — where the treating doctor determines participation would not be appropriate
  • People with a history of an organ transplant, where the treating doctor determines participation would not be appropriate
  • People who have received immune system treatment for a kidney condition within the 6 months before enrolling
  • People with severe heart failure classified as Class IV by their doctor
  • People who have had a heart attack, unstable chest pain, stroke, or mini-stroke (TIA) within the 12 weeks before enrolling
  • People who have had a heart procedure (such as stenting, bypass surgery, or heart valve repair) within the 12 weeks before enrolling
  • People who are currently receiving hospice care
  • People with an active cancer requiring treatment, where the treating doctor determines participation would not be appropriate
  • People with severe liver disease (decompensated cirrhosis), as determined by their doctor
  • People with cognitive (thinking or memory) difficulties that would prevent participation, as identified during enrollment screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maninder Kahlon, PhD, University of Texas at Austin

Phone: 512-522-4349

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Texas at Austin
Registry
ClinicalTrials.gov
Start date
6 December 2023
Est. completion
1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Urine albumin:creatinine ratio (UACR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov